ÂÜÀòÂÒÂ×

Scott Clarke is an accomplished executive with extensive experience in the biotechnology and pharmaceutical industries. Since January 2023, Scott serves as a Board Member at NovalGen and has held the position of CEO at Ambagon Therapeutics since February 2021. Additionally, Scott has served on the board and as CEO at Trishula Therapeutics, Inc. since August 2020, and previously held similar roles at Tizona Therapeutics, Inc. until March 2021. Prior to these positions, Scott was the Global Head of Oncology Partnering and Head of Asia & Emerging Markets Partnering at Roche from April 2017 to December 2018. Scott's career at BioMarin Pharmaceutical Inc. spanned over a decade, where Scott progressed through various roles, including Senior Vice President of Product Development. Scott's educational background includes an MBA from London Business School, a BS in Chemical Engineering from the University of California, Berkeley, and an MS in Biotechnology from Northwestern University.